Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-198
Closed -$15K 3686
2026
Q1
$15K Sell
198
-2,020
-91% -$152K ﹤0.01% 1507
2025
Q4
$165K Buy
2,218
+1,612
+266% +$118K ﹤0.01% 969
2025
Q3
$40.9K Buy
606
+11
+2% +$730 ﹤0.01% 1340
2025
Q2
$38.8K Buy
595
+239
+67% +$14.3K ﹤0.01% 1372
2025
Q1
$22K Buy
356
+53
+17% +$3.51K ﹤0.01% 1402
2024
Q4
$21.8K Hold
303
﹤0.01% 1357
2024
Q3
$24.7K Hold
303
﹤0.01% 1370
2024
Q2
$22.5K Buy
+303
New +$22.7K ﹤0.01% 1342
2024
Q1
Sell
-17
Closed -$1.22K 1580
2023
Q4
$1.22K Buy
+17
New +$1.18K ﹤0.01% 1378
2023
Q2
Sell
-15
Closed -$1.21K 1405
2023
Q1
$1.21K Buy
+15
New +$1.21K ﹤0.01% 1205
2022
Q3
Sell
-59
Closed -$4K 1295
2022
Q2
$4K Buy
+59
New +$4.38K ﹤0.01% 1028
2021
Q3
Sell
-21
Closed -$1K 1329
2021
Q2
$1K Buy
+21
New +$1.4K ﹤0.01% 1155

Other funds holding HOLX

Clearstead Advisors's HOLX Position: Q2 2026 in Review

Clearstead Advisors sold out of Hologic (HOLX) in Q2 2026, closing a stake of 198 shares — an estimated $15K sold.

Clearstead Advisors first reported a position in HOLX in Q2 2021 and held it in 12 quarters. The position peaked at $165K in Q4 2025. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • Clearstead Advisors reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • Clearstead Advisors sold 198 Hologic shares in Q2 2026, an estimated $15K.
  • Clearstead Advisors first reported a position in Hologic in Q2 2021 and held it in 12 quarters.
  • Clearstead Advisors's Hologic position peaked at $165K in Q4 2025.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.